In Combo Studies for the Optimization of 5-Aminoanthranilic Acid Derivatives as Potential Multitarget Drugs for the Management of Metabolic Syndrome
暂无分享,去创建一个
Juan Rodrigo Salazar | C. Guerra-Araiza | Marco A. Loza-Mejía | A. Ariza-Castolo | R. Pinto-Almazán | M. R. Ayala-Moreno | E. Chávez-Gutiérrez | L. Rodríguez-Páez | O. J. Quintana-Romero | Matilda Martínez-Arellanes | Montserrat Murillo-López | María Fernanda Medina-Guzmán | Laila Mobarak-Richaud | Karen Pelcastre-Guzmán
[1] A. M. Inarejos-García,et al. Supplementation with Two New Standardized Tea Extracts Prevents the Development of Hypertension in Mice with Metabolic Syndrome , 2022, Antioxidants.
[2] G. Albadrani,et al. The Role of Myrrh Metabolites in Cancer, Inflammation, and Wound Healing: Prospects for a Multi-Targeted Drug Therapy , 2022, Pharmaceuticals.
[3] S. Sestito,et al. Design, Synthesis, and In Vitro Evaluation of Novel 8-Amino-Quinoline Combined with Natural Antioxidant Acids , 2022, Pharmaceuticals.
[4] A. Stringaro,et al. Design, Synthesis, and In Vitro, In Silico and In Cellulo Evaluation of New Pyrimidine and Pyridine Amide and Carbamate Derivatives as Multi-Functional Cholinesterase Inhibitors , 2022, Pharmaceuticals.
[5] N. Subbarao,et al. Discovery of multi-target mur enzymes inhibitors with anti-mycobacterial activity through a Scaffold approach , 2022, Journal of biomolecular structure & dynamics.
[6] K. Ma,et al. Bezafibrate Exerts Neuroprotective Effects in a Rat Model of Sporadic Alzheimer’s Disease , 2022, Pharmaceuticals.
[7] G. Navarrete-Vázquez,et al. Synthesis, In Vitro, In Vivo and In Silico Antidiabetic Bioassays of 4-Nitro(thio)phenoxyisobutyric Acids Acting as Unexpected PPARγ Modulators: An In Combo Study , 2022, Pharmaceuticals.
[8] H. Assi,et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021 , 2022, International journal of molecular sciences.
[9] A. Muth,et al. Polypharmacology: The Science of Multi-targeting Molecules. , 2022, Pharmacological research.
[10] C. Cervellati,et al. Prognostic Role of Metabolic Syndrome in COVID-19 Patients: A Systematic Review Meta-Analysis , 2021, Viruses.
[11] C. Yun,et al. A Novel Statin Compound from Monacolin J Produced Using CYP102A1-Catalyzed Regioselective C-Hydroxylation , 2021, Pharmaceuticals.
[12] C. Guerra-Araiza,et al. In Silico-Based Design and In Vivo Evaluation of an Anthranilic Acid Derivative as a Multitarget Drug in a Diet-Induced Metabolic Syndrome Model , 2021, Pharmaceuticals.
[13] A. Astrup,et al. The triglyceride‐glucose index as an adiposity marker and a predictor of fat loss induced by a low‐calorie diet , 2021, European journal of clinical investigation.
[14] R. Mercadillo,et al. Nutritional Status Influences Oxidative Stress and Insulin Resistance in Preschool Children. , 2021, Metabolic syndrome and related disorders.
[15] Marine Peuchmaur,et al. β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy. , 2021, Journal of medicinal chemistry.
[16] Kyungdo Han,et al. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study , 2020, BMC Medicine.
[17] S. Müller,et al. A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice , 2020, Communications Chemistry.
[18] M. Holeček,et al. Effects of low and high doses of fenofibrate on protein, amino acid, and energy metabolism in rat , 2020, International journal of experimental pathology.
[19] F. Hsiao,et al. Combined Effects of Frailty and Polypharmacy on Health Outcomes in Older Adults: Frailty Outweighs Polypharmacy. , 2020, Journal of the American Medical Directors Association.
[20] F. J. Luque,et al. Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. , 2020, Journal of medicinal chemistry.
[21] R. Muniyappa,et al. Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course , 2020, Endocrinology.
[22] C. Espinosa-Garcia,et al. Sex differences in the performance of cognitive tasks in a murine model of metabolic syndrome , 2020, The European journal of neuroscience.
[23] M. Rarey,et al. ProteinsPlus: interactive analysis of protein–ligand binding interfaces , 2020, Nucleic Acids Res..
[24] Juan Francisco Sánchez-Tejeda,et al. A Definition of “Multitargeticity”: Identifying Potential Multitarget and Selective Ligands Through a Vector Analysis , 2020, Frontiers in Chemistry.
[25] A. Sureda,et al. Metabolic Syndrome Is Associated with Oxidative Stress and Proinflammatory State , 2020, Antioxidants.
[26] B. Hanratty,et al. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. , 2020, Journal of the American Medical Directors Association.
[27] S. Yamashita,et al. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases , 2020, Current Atherosclerosis Reports.
[28] C. Supuran,et al. New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment. , 2019, European journal of medicinal chemistry.
[29] A. Ammazzalorso,et al. Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome. , 2019, European journal of medicinal chemistry.
[30] Peter W. Kenny,et al. The nature of ligand efficiency , 2018, Journal of Cheminformatics.
[31] D. Hadjipavlou-Litina,et al. Cinnamate Hybrids: A Unique Family of Compounds with Multiple Biological Activities. , 2019, Current pharmaceutical biotechnology.
[32] Shaodong Guo,et al. Etiology of Metabolic Syndrome and Dietary Intervention , 2018, International journal of molecular sciences.
[33] Juan Francisco Sánchez-Tejeda,et al. In Silico Studies on Compounds Derived from Calceolaria: Phenylethanoid Glycosides as Potential Multitarget Inhibitors for the Development of Pesticides , 2018, Biomolecules.
[34] Fernanda I. Saldívar-González,et al. Inhibitors of DNA Methyltransferases From Natural Sources: A Computational Perspective , 2018, Front. Pharmacol..
[35] A. Vega‐Gálvez,et al. Evaluation of phenolic profiles and antioxidant capacity of maqui (Aristotelia chilensis) berries and their relationships to drying methods. , 2018, Journal of the science of food and agriculture.
[36] S. Tuntipopipat,et al. Ferulic Acid Supplementation Improves Lipid Profiles, Oxidative Stress, and Inflammatory Status in Hyperlipidemic Subjects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial , 2018, Nutrients.
[37] V. Sládek,et al. Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα. , 2018, Biochemical and biophysical research communications.
[38] Tariq M. Alhawassi,et al. Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia , 2018, BMJ Open.
[39] P. Paoli,et al. Ursolic acid derivatives as potential antidiabetic agents: In vitro, in vivo, and in silico studies , 2018, Drug development research.
[40] M. Saklayen. The Global Epidemic of the Metabolic Syndrome , 2018, Current Hypertension Reports.
[41] E. Hernández-Núñez,et al. Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids † , 2018, Molecules.
[42] Rona R. Ramsay,et al. A perspective on multi-target drug discovery and design for complex diseases , 2018, Clinical and Translational Medicine.
[43] S. Sreenivasan,et al. Pathophysiology of the metabolic syndrome. , 2018, Clinics in dermatology.
[44] Y. Im,et al. Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs , 2017, Scientific Reports.
[45] N. Karp,et al. A high-throughput in vivo screening method in the mouse for identifying regulators of metastatic colonization , 2017, Nature Protocols.
[46] Gillian E. Caughey,et al. What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.
[47] Gerd Geisslinger,et al. A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. , 2017, Journal of medicinal chemistry.
[48] N. Mishra,et al. Synthesis and anti-inflammatory evaluation of N-sulfonyl anthranilic acids via Ir(III)-catalyzed C-H amidation of benzoic acids. , 2017, Bioorganic & medicinal chemistry letters.
[49] Weilin Zhang,et al. Computational Multitarget Drug Design , 2017, J. Chem. Inf. Model..
[50] A. Cavalli,et al. Multitarget Drug Discovery and Polypharmacology , 2016, ChemMedChem.
[51] J. Martínez,et al. Triglyceride-glucose index (TyG index) in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose: The Vascular-Metabolic CUN cohort. , 2016, Preventive medicine.
[52] S. Grundy. Metabolic syndrome update. , 2016, Trends in cardiovascular medicine.
[53] A. Cavalli,et al. Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease , 2016, Molecules.
[54] L. Rabelo,et al. Aging Increases Susceptibility to High Fat Diet-Induced Metabolic Syndrome in C57BL/6 Mice: Improvement in Glycemic and Lipid Profile after Antioxidant Therapy , 2016, Oxidative medicine and cellular longevity.
[55] Antonio Lavecchia,et al. In silico methods to address polypharmacology: current status, applications and future perspectives. , 2016, Drug discovery today.
[56] Juan Rodrigo Salazar,et al. Sterols and triterpenoids as potential anti-inflammatories: Molecular docking studies for binding to some enzymes involved in inflammatory pathways. , 2015, Journal of molecular graphics & modelling.
[57] S. Masuda,et al. Identification of a New Type of Covalent PPARγ Agonist using a Ligand-Linking Strategy. , 2015, ACS chemical biology.
[58] Alan Talevi,et al. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective , 2015, Front. Pharmacol..
[59] S. Greenwald,et al. Ferulic Acid Alleviates Changes in a Rat Model of Metabolic Syndrome Induced by High-Carbohydrate, High-Fat Diet , 2015, Nutrients.
[60] Douglas E. V. Pires,et al. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.
[61] M. Schubert-Zsilavecz,et al. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands. , 2015, Bioorganic & medicinal chemistry.
[62] Oliver Werz,et al. Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.
[63] Aarón Mendieta,et al. Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors. , 2014, Bioorganic & medicinal chemistry.
[64] Xuefeng Yu,et al. O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .
[65] B. Ma,et al. Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats , 2014, Acta Pharmacologica Sinica.
[66] A. Kourounakis,et al. Multi-target drug design approaches for multifactorial diseases: from neurodegenerative to cardiovascular applications. , 2014, Current medicinal chemistry.
[67] Hyung-Sik Kang,et al. Chimeric cytochromes P450 engineered by domain swapping and random mutagenesis for producing human metabolites of drugs , 2014, Biotechnology and bioengineering.
[68] G. Schneider,et al. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR). , 2014, Bioorganic & medicinal chemistry.
[69] J. Medina-Franco,et al. Synthesis of 2-{2-[(α/β-naphthalen-1-ylsulfonyl)amino]-1,3-thiazol-4-yl} acetamides with 11β-hydroxysteroid dehydrogenase inhibition and in combo antidiabetic activities. , 2014, European journal of medicinal chemistry.
[70] M. Youdim,et al. From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy , 2014, Pharmaceuticals.
[71] Hai-bin Luo,et al. Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. , 2013, Journal of medicinal chemistry.
[72] J. Medina-Franco,et al. Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent. , 2013, Bioorganic & medicinal chemistry letters.
[73] H. Roche,et al. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study , 2013, Experimental & Molecular Medicine.
[74] Alejandro Speck-Planche,et al. Fragment-based approach for the in silico discovery of multi-target insecticides , 2012 .
[75] A. Oladejo,et al. OVERVIEW OF THE METABOLIC SYNDROME; AN EMERGING PANDEMIC OF PUBLIC HEALTH SIGNIFICANCE , 2011, Annals of Ibadan postgraduate medicine.
[76] Alejandro Speck-Planche,et al. Current computational approaches towards the rational design of new insecticidal agents. , 2011, Current computer-aided drug design.
[77] L. Brown,et al. Rodent Models for Metabolic Syndrome Research , 2010, Journal of biomedicine & biotechnology.
[78] C. Thiemermann,et al. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation , 2010, British journal of pharmacology.
[79] J. Imig,et al. Simvastatin and Tempol Protect Against Endothelial Dysfunction and Renal Injury in a Model of Obesity and Hypertension , 2008, American journal of physiology. Renal physiology.
[80] R. Apak,et al. Cupric ion reducing antioxidant capacity assay for antioxidants in human serum and for hydroxyl radical scavengers. , 2010, Methods in molecular biology.
[81] D. Armstrong. Advanced Protocols in Oxidative Stress II , 2010, Methods in Molecular Biology.
[82] Craig K. Abbey,et al. High-throughput in vivo screening of targeted molecular imaging agents , 2009, Proceedings of the National Academy of Sciences.
[83] M. Rodríguez-Moran,et al. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. , 2008, Metabolic syndrome and related disorders.
[84] Ardiansyah,et al. Novel effects of a single administration of ferulic acid on the regulation of blood pressure and the hepatic lipid metabolic profile in stroke-prone spontaneously hypertensive rats. , 2008, Journal of agricultural and food chemistry.
[85] T. Dusek,et al. Pathophysiology of Metabolic Syndrome , 2007, EJIFCC.
[86] S. Grundy. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy , 2006, Nature Reviews Drug Discovery.
[87] Richard Kahn,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.
[88] R. Kahn,et al. The metabolic syndrome: time for a critical appraisal , 2005, Diabetologia.
[89] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[90] S. Grundy. Metabolic syndrome: therapeutic considerations. , 2005, Handbook of experimental pharmacology.
[91] C. Wong,et al. Alpha-asarone inhibits HMG-CoA reductase, lowers serum LDL-cholesterol levels and reduces biliary CSI in hypercholesterolemic rats. , 2003, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[92] F. Leighton,et al. Juice and phenolic fractions of the berry Aristotelia chilensis inhibit LDL oxidation in vitro and protect human endothelial cells against oxidative stress. , 2002, Journal of agricultural and food chemistry.
[93] F. C. Nelson,et al. The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. , 2001, Bioorganic & medicinal chemistry letters.
[94] R. Buckingham,et al. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution , 1999, British journal of pharmacology.